In this video, Felipe Prosper, MD, PhD, University of Navarra, Pamplona, Spain, reports on a study that evaluated the impact of CAR density on the efficacy of anti-BCMA CAR-T cells in patients with multiple myeloma. Patients treated with CAR-T cell products with low CAR expression had significantly better clinical responses. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.